Thor Medical ASA (LTS:0R6Y)

kr 2.64 0 (0%) Market Cap: 744.71 Mil Enterprise Value: 716.01 Mil PE Ratio: 0 PB Ratio: 2.40 GF Score: 32/100

Q2 2023 Thor Medical ASA Earnings Call Transcript
Aug 31, 2023

kr1.33 (+0.30%)

Earnings
Nordic Nanovector ASA Thor Medical As - M&A Call Transcript
Jun 07, 2023
Q4 2022 Nordic Nanovector ASA Earnings Call Transcript
Feb 28, 2023

kr1.04

Earnings
Nordic Nanovector ASA Webcast to Discuss the Merger Transcript
Nov 24, 2022
Nordic Nanovector ASA M&A Call Transcript
Nov 10, 2022
Q2 2022 Nordic Nanovector ASA Earnings Call Transcript
Aug 31, 2022

kr1.8 (-17.92%)

Earnings
Nordic Nanovector ASA -PARADIGME Update Transcript
Jul 06, 2022
Q1 2022 Nordic Nanovector ASA Earnings Call Transcript
May 13, 2022

kr11.01 (-20.46%)

Earnings
Q4 2021 Nordic Nanovector ASA Earnings Presentation Transcript
Mar 01, 2022
Nordic Nanovector ASA Extraordinary Shareholders Meeting Transcript
Feb 14, 2022
Nordic Nanovector ASA - R&D Day Transcript
Nov 30, 2021
Q3 2021 Nordic Nanovector ASA Earnings Call Transcript
Nov 18, 2021

kr25.76 (-7.94%)

Earnings
Q2 2021 Nordic Nanovector ASA Earnings Call Transcript
Aug 27, 2021

kr21.16 (+11.15%)

Earnings
Nordic Nanovector ASA Corporate Call Transcript
Aug 05, 2021
Q1 2021 Nordic Nanovector ASA Earnings Presentation Transcript
May 26, 2021
Nordic Nanovector ASA Annual Shareholders Meeting Transcript
Apr 28, 2021
Nordic Nanovector ASA Extraordinary Shareholders Meeting Transcript
Mar 22, 2021
Q4 2020 Nordic Nanovector ASA Earnings Call Transcript
Feb 18, 2021

kr19.66 (+44.34%)

Earnings
Q3 2020 Nordic Nanovector ASA Earnings Call Transcript
Nov 19, 2020

kr14.46 (-4.78%)

Earnings
Nordic Nanovector ASA Extraordinary Shareholders Meeting Transcript
Oct 21, 2020
Q2 2020 Nordic Nanovector ASA Earnings Call Transcript
Aug 27, 2020

kr23.82 (-14.47%)

Earnings
Nordic Nanovector ASA Annual Shareholders Meeting Transcript
Jun 10, 2020
Q1 2020 Nordic Nanovector ASA Earnings Call Transcript
May 26, 2020

kr20.1 (-12.15%)

Earnings
Nordic Nanovector ASA to Focus on Advancing PARADIGME and Actions to Extend Cash Runway Into 2021 Presentation Transcript
Apr 02, 2020
Q4 2019 Nordic Nanovector ASA Earnings Call Transcript
Feb 27, 2020

kr15.48 (-32.21%)

Earnings
Q3 2019 Nordic Nanovector ASA Earnings Call Transcript
Nov 19, 2019

kr20.17 (-1.26%)

Earnings
Nordic Nanovector ASA - Special Call Transcript
Sep 17, 2019
Q2 2019 Nordic Nanovector ASA Earnings Presentation Transcript
Aug 22, 2019
Q1 2019 Nordic Nanovector ASA Earnings Call Transcript
May 23, 2019

kr41.76 (-4.86%)

Earnings

Q4 2022 Nordic Nanovector ASA Earnings Call Transcript

Feb 28, 2023 / 07:30AM GMT

Release Date Price: kr1.04

Transcript

Ludvik Sandnes

Nordic Nanovector ASA - Interim CEO & CFO

Good morning, everyone, and thank you for joining this 2022 presentation. I'm Ludvik Sandnes, and I will, on behalf of the former Board of Directors and the CEO explain what happened last year. They had a very active year with 27 Board meetings. And my presentation will be recorded, so I therefore take questions at the end. And I hope the details given in this presentation will answer most of the questions you might have.

As an update, last year became an annus horribilis for Nordic Nanovector. Betalutin/PARADIGME had to be discontinued, as you know, due to continued severe difficulties in the enrolling of patients, the impact of COVID-19 as for many other studies, disappointing regulatory feasibility, evaluation and poor efficacy data; below threshold values set for the study and noncompetitive profile in the crowded market going forward. Independent review concluded that the efficacy data would not give Betalutin a competitive profile in third-line follicular lymphoma. The company restructure was initiated in the second half and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.